REACT: A prospective, multicenter, double-blind, randomized, placebo controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects wit aneurysmal subarachnoid hemorrhage (aSAH) - Investigador Principal: Jose F Alen; Guillermo Blasco; Natalia Frade; Patricia Gonzalez Tarno; Alfonso Canabal (2020)